TICKERNERD
Menu
HYPRHealthcare · Medical Devices

HYPR Stock Forecast: Hyperfine, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.90
−0.30% on the day

The 3 Wall Street analysts covering Hyperfine, Inc. hold a median 12-month price target of $2 — +121.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$95.7M
Ticker Nerd rank
56 / 100
Median analyst target
$2.00
Analysts covering
3
Total return, dividends reinvested
1W
+0.9%
1M
−9.0%
YTD
−7.9%
1Y
−26.7%
From 52W high
−59.0%
From 52W low
+1.2%
$0.89
$2.20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HYPR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Hyperfine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
56 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
98
Revisions
89
Size
76
Accruals
56
Volatility
46
Momentum
35
Quality
33
Value
24
Issuance
8

Growth (98): Sales and profits are climbing, and climbing faster than before.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HYPR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HYPR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$1.50$2.00$2.50Oct 25Jan 26Apr 26Jul 26HYPRHigh $2.50Median $2.00Low $1.60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $1.60Median $2.00High $2.50

The green dot is the last close — the median target sits +121.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Aug 2026B. Riley SecuritiesReiteratesBuy$2.00 → $1.60
29 Apr 2026BTIGInitiatesBuy$2.00
29 Apr 2026BTIGInitiatesBuy—
19 Mar 2026Lake StreetMaintainsBuy—
15 Aug 2025Wells FargoMaintainsEqual-Weight—
14 Aug 2025Lake StreetMaintainsBuy—
15 May 2025B. Riley SecuritiesMaintainsBuy—
14 May 2025Wells FargoMaintainsEqual-Weight—
24 Mar 2025Lake StreetInitiatesBuy—
20 Mar 2025B. Riley SecuritiesMaintainsBuy—
18 Mar 2025Wells FargoMaintainsEqual-Weight—
22 Mar 2024Wells FargoMaintainsEqual-Weight—
30 Nov 2023JefferiesInitiatesHold—
15 Aug 2023B. Riley SecuritiesMaintainsBuy—
22 Mar 2023B. Riley SecuritiesMaintainsBuy—
4 Oct 2022B. Riley SecuritiesInitiatesBuy—
11 Aug 2022Wells FargoDowngradeEqual-Weight—
31 May 2022Evercore ISI GroupInitiatesOutperform—
14 Apr 2022Wells FargoInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HYPR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

HYPR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Hyperfine, Inc. (HYPR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.1×

Cheaper than 85% of US stocks

Price / sales
5.8×

Cheaper than 23% of US stocks

Price / book
2.6×

Cheaper than 39% of US stocks

EV / EBITDA
−2.0×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
44.8%

Higher than 85% of US stocks

Earnings growth (YoY)
44.8%

Higher than 73% of US stocks

Gross margin
50.7%

Higher than 63% of US stocks

Operating margin
−216.9%

Higher than 10% of US stocks

Net margin
−210.8%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−97.0%

Higher than 13% of US stocks

Return on assets
−38.8%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

HYPR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
HYPRHyperfine, Inc.$95.7M
56
ECORelectroCore, Inc.$94.8M
54
LUNGPulmonx Corp.$93.2M
74
MBOTMicrobot Medical, Inc.$100.7M
15
LNSRLENSAR, Inc.$103.6M
60
SERASera Prognostics, Inc.$83.8M
40
RPIDRapid Micro Biosystems, Inc.$83.7M
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Hyperfine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HYPR news & analysis

Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

Business Wire · 20 Aug 2026positive

Hyperfine announced FDA clearance of its next Optive AI software, which enhances image quality, clinical utility, ease of use, and isotropic imaging capability of its Swoop system across care settings.

Why it matters — A HYPR watcher would care because the FDA clearance strengthens the Swoop system's offering, potentially broadening its clinical and market applicability.

Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the transcript of Hyperfine, Inc.'s Q2 2026 earnings call, covering the company's quarterly results and management commentary.

Why it matters — A Hyperfine watcher would rely on this transcript for management's detailed discussion of the company's quarterly performance.

Hyperfine Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Hyperfine reported second-quarter revenue of $3.9 million, up approximately 45% from a year earlier, in its Q2 earnings call. The portable MRI company attributed the growth to gains across hospital, neurology office, and international markets.

Why it matters — A 45% year-over-year revenue increase signals expanding adoption of Hyperfine's portable MRI across multiple market segments, which is a key indicator for HYPR watchers tracking the company's commercial momentum.

Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 7 Aug 2026neutral

Hyperfine, Inc. reported a second-quarter loss of $0.09 per share, in line with the Zacks Consensus Estimate and improved from a $0.12 per-share loss a year earlier. The report also indicates revenue fell short of estimates.

Why it matters — A HYPR watcher would care because the per-share loss met analyst expectations and narrowed from the prior-year quarter, though revenue missed estimates.

Hyperfine, Inc. Reports Second Quarter 2026 Financial Results

Business Wire · 6 Aug 2026positive

Hyperfine, Inc. announced its second quarter 2026 financial results and provided a business update. The company cited strong growth in placements and revenue, continued gross margin expansion, and disciplined operating expenses.

Why it matters — A HYPR watcher would care because the company's placement and revenue growth, along with gross margin expansion, indicate the trajectory of its portable brain imaging system adoption.

FAQ

Frequently asked questions about HYPR stock

What is the HYPR stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Hyperfine, Inc. have a median 12-month price target of $2, with estimates ranging from $1.6 to $2.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HYPR stock a buy right now?

Of the 3 analysts covering Hyperfine, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Hyperfine, Inc. 56 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HYPR?

As at 22 Aug 2026, Hyperfine, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).

Will HYPR stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +121.9% from the last close, and Ticker Nerd's factor model ranks Hyperfine, Inc. 56 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HYPR stock forecast for 2030?

No analyst covering Hyperfine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HYPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.6 to $2.5 over the next 12 months.

How has HYPR stock performed over the past year?

Hyperfine, Inc. returned -26.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Hyperfine, Inc. do?

Hyperfine Inc., a pioneering medical technology firm, develops portable, low-cost magnetic resonance imaging (MRI) systems known for their accessibility and transformative potential in healthcare. Hyperfine's flagship product, the Swoop Portable MRI, is designed to significantly enhance patient care by enabling real-time, bedside imaging, thus extending MRI capabilities beyond traditional clinical settings.

What is the latest news on HYPR?

The most recent item we track (Business Wire, 20 Aug 2026): "Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings". Hyperfine announced FDA clearance of its next Optive AI software, which enhances image quality, clinical utility, ease of use, and isotropic imaging capability of its Swoop system across care settings.

Company

About Hyperfine, Inc.

Hyperfine Inc., a pioneering medical technology firm, develops portable, low-cost magnetic resonance imaging (MRI) systems known for their accessibility and transformative potential in healthcare. Hyperfine's flagship product, the Swoop Portable MRI, is designed to significantly enhance patient care by enabling real-time, bedside imaging, thus extending MRI capabilities beyond traditional clinical settings. This innovation is particularly impactful in emergency rooms, intensive care units, and remote locations where access to conventional MRI facilities may be limited or non-existent. By bridging the gap between advanced imaging and practical application, Hyperfine Inc. plays a crucial role in democratizing healthcare access, speeding up diagnosis, and ultimately improving clinical outcomes. The company’s focus on innovation and accessibility positions it as a key player in the med-tech industry, potentially influencing hospital operations, patient management protocols, and healthcare delivery frameworks worldwide.

CEO Ms. Maria Degois-Sainz · 102 employees · United States · https://www.hyperfinemri.com